| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.05 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.05 |